170 related articles for article (PubMed ID: 36630995)
1. Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
Guillot A; Winkler M; Silva Afonso M; Aggarwal A; Lopez D; Berger H; Kohlhepp MS; Liu H; Özdirik B; Eschrich J; Ma J; Peiseler M; Heymann F; Pendem S; Mahadevan S; Gao B; Diehl L; Gupta R; Tacke F
Hepatology; 2023 Jul; 78(1):150-166. PubMed ID: 36630995
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.
Elßner C; Goeppert B; Longerich T; Scherr AL; Stindt J; Nanduri LK; Rupp C; Kather JN; Schmitt N; Kautz N; Breuhahn K; Ismail L; Heide D; Hetzer J; García-Beccaria M; Hövelmeyer N; Waisman A; Urbanik T; Mueller S; Gdynia G; Banales JM; Roessler S; Schirmacher P; Jäger D; Schölch S; Keitel V; Heikenwalder M; Schulze-Bergkamen H; Köhler BC
Gastroenterology; 2019 Mar; 156(4):1190-1205.e14. PubMed ID: 30445013
[TBL] [Abstract][Full Text] [Related]
3. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
4. Soluble TREM2 levels reflect the recruitment and expansion of TREM2
Hendrikx T; Porsch F; Kiss MG; Rajcic D; Papac-Miličević N; Hoebinger C; Goederle L; Hladik A; Shaw LE; Horstmann H; Knapp S; Derdak S; Bilban M; Heintz L; Krawczyk M; Paternostro R; Trauner M; Farlik M; Wolf D; Binder CJ
J Hepatol; 2022 Nov; 77(5):1373-1385. PubMed ID: 35750138
[TBL] [Abstract][Full Text] [Related]
5. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
6. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
Andrews TS; Nakib D; Perciani CT; Ma XZ; Liu L; Winter E; Camat D; Chung SW; Lumanto P; Manuel J; Mangroo S; Hansen B; Arpinder B; Thoeni C; Sayed B; Feld J; Gehring A; Gulamhusein A; Hirschfield GM; Ricciuto A; Bader GD; McGilvray ID; MacParland S
J Hepatol; 2024 May; 80(5):730-743. PubMed ID: 38199298
[TBL] [Abstract][Full Text] [Related]
7. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
Jin K; Shi Y; Zhang H; Zhangyuan G; Wang F; Li S; Chen C; Zhang J; Wang H; Zhang W; Sun B
J Hepatol; 2023 Aug; 79(2):403-416. PubMed ID: 37040844
[TBL] [Abstract][Full Text] [Related]
8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
9. Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH.
Fredrickson G; Barrow F; Dietsche K; Parthiban P; Khan S; Robert S; Demirchian M; Rhoades H; Wang H; Adeyi O; Revelo XS
Mol Metab; 2021 Nov; 53():101270. PubMed ID: 34118476
[TBL] [Abstract][Full Text] [Related]
10. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.
Krenkel O; Hundertmark J; Abdallah AT; Kohlhepp M; Puengel T; Roth T; Branco DPP; Mossanen JC; Luedde T; Trautwein C; Costa IG; Tacke F
Gut; 2020 Mar; 69(3):551-563. PubMed ID: 31076404
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis.
Chen YY; Arndtz K; Webb G; Corrigan M; Akiror S; Liaskou E; Woodward P; Adams DH; Weston CJ; Hirschfield GM
JHEP Rep; 2019 Nov; 1(5):369-376. PubMed ID: 32039388
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis.
Dhingra S; Mahadik JD; Tarabishy Y; May SB; Vierling JM
Pathology; 2022 Oct; 54(6):686-693. PubMed ID: 35525796
[TBL] [Abstract][Full Text] [Related]
14. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
15. [Macrophage heterogeneity role in NAFLD and NASH disease progression].
Yang T; Wang X; Jiang LF; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):770-775. PubMed ID: 37580264
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.
Bosch DE; Zen Y; Boukhar SA; Liu Y; Cheng L; Yeh MM
Virchows Arch; 2021 Dec; 479(6):1131-1143. PubMed ID: 34414507
[TBL] [Abstract][Full Text] [Related]
17. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis.
Sasatomi K; Noguchi K; Sakisaka S; Sata M; Tanikawa K
J Hepatol; 1998 Sep; 29(3):409-16. PubMed ID: 9764987
[TBL] [Abstract][Full Text] [Related]
18. Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages.
He W; Huang Y; Shi X; Wang Q; Wu M; Li H; Liu Q; Zhang X; Huang C; Li X
J Transl Med; 2023 Jul; 21(1):448. PubMed ID: 37415134
[TBL] [Abstract][Full Text] [Related]
19. Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis.
Rothweiler S; Feldbrügge L; Jiang ZG; Csizmadia E; Longhi MS; Vaid K; Enjyoji K; Popov YV; Robson SC
Purinergic Signal; 2019 Sep; 15(3):375-385. PubMed ID: 31243614
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
